1/125
Looks like no tags are added yet.
What is the core pathophysiology of heart failure (HF)?
The heart is unable to supply sufficient oxygen-rich blood to the body due to an impaired ability of the left ventricle to either fill with blood during diastole (relaxation) or eject blood during systole (contraction).
What are the most common and less common causes of heart failure?
Most common: Ischemic conditions (e.g., MI) and non-ischemic conditions (e.g., chronic, uncontrolled hypertension). Less common: Valvular disease, excessive alcohol intake, illicit drug use, congenital heart defects, viral infections, diabetes, and cardiotoxic drugs/chest radiation.
What are the two primary mechanisms driving the signs and symptoms of heart failure?
Fluid overload (commonly presenting as edema) and low blood volume (or oxygen) delivery to organs.
How do the underlying causes of "left-sided" vs. "right-sided" HF symptoms differ?
Left-sided: Backed-up fluid in the heart and lungs due to left ventricular failure. Right-sided: Backed-up fluid in the periphery/systemic circulation due to right ventricular failure.
What are the normal lab values for BNP and NT-proBNP, and what is their clinical purpose in HF?
BNP (B-type natriuretic peptide): Normal is < 100 pg/mL (elevated in HF). NT-proBNP (Nterminal proBNP): Normal is < 300 pg/mL (elevated in HF). Purpose: Used to distinguish between cardiac and non-cardiac causes of dyspnea.
What are the general signs and symptoms of heart failure?
Dyspnea (SOB at rest or during exertion); Cough; Fatigue and weakness; Reduced exercise capacity.
What are the left-sided signs and symptoms of heart failure?
Orthopnea: Shortness of breath (SOB) when lying flat; Paroxysmal nocturnal dyspnea (PND): Nocturnal cough and SOB; Bibasilar rales: Crackling sounds heard on lung exam; S3 gallop: An extra, abnormal heart sound; Hypoperfusion: e.g., renal impairment, cool extremities.
What are the right-sided signs and symptoms of heart failure?
Peripheral edema; Ascites (abdominal fluid accumulation); Jugular venous distention (JVD); Hepatojugular reflux (HJR): Neck vein distention (JVD) from pressure placed on the abdomen; Hepatomegaly (enlarged liver).
What diagnostic test estimates left ventricular ejection fraction (LVEF), and what does LVEF measure?
An ultrasound of the heart (echocardiography or echo) estimates LVEF, which is the percentage of blood pumped out of the left ventricle with each contraction.
What ejection fraction (EF) threshold defines heart failure with reduced ejection fraction (HFrEF)?
An EF < 40% (or <= 40%) indicates systolic dysfunction, or HFrEF.
What is a normal Left Ventricular Ejection Fraction (LVEF)?
55–70%
What defines Heart Failure with Preserved EF (HFpEF), and what is its primary problem?
LVEF:
= 50%. Alternative Term: Diastolic Dysfunction. Primary Problem: Impaired ventricular relaxation and filling during diastole.
What defines Heart Failure with Mildly Reduced EF (HFmrEF), and what is its primary problem?
LVEF: 41–49%. Primary Problem: Likely mixed systolic and diastolic dysfunction.
What defines Heart Failure with Reduced EF (HFrEF), and what is its primary problem?
LVEF: <= 40%. Alternative Term: Systolic Dysfunction. Primary Problem: Impaired ability to eject blood during systole.
What defines Heart Failure with Improved EF (HFimpEF), and how does it affect treatment?
LVEF:
What is the purpose of the ACC/AHA Heart Failure Staging System vs. the NYHA Classification System?
ACC/AHA Staging System: Used to guide treatment to slow the progression of structural heart disease (e.g., LVH, low EF) in both asymptomatic (stages A and B) and symptomatic (stages C and D) patients. NYHA Classification System: Classifies HF based on limitations in physical functioning.
Describe ACC/AHA Stage A heart failure and its corresponding NYHA class.
Definition: At risk for HF, but without symptoms, structural heart disease, or elevated biomarkers. Examples: Patients with hypertension, ASCVD, or diabetes. NYHA Class: No corresponding category.
Describe ACC/AHA Stage B heart failure and its corresponding NYHA class.
Definition: Pre-HF; structural heart disease and/or elevated biomarkers, but without HF signs or symptoms. Examples: Patients with LVH, low EF, or valvular disease. NYHA Class: Class I (No limitations of physical activity; ordinary physical activity does not cause HF symptoms like fatigue, palpitations, or dyspnea).
Describe ACC/AHA Stage C heart failure and its corresponding NYHA classes.
Definition: Clinical diagnosis of HF; structural heart disease with prior or current symptoms of HF (e.g., known LVH plus shortness of breath, fatigue, and reduced exercise tolerance). NYHA Classes: Class I, II, III, or IV.
Describe ACC/AHA Stage D heart failure and its corresponding NYHA class.
Definition: Clinical diagnosis of HF; advanced (refractory) HF with severe symptoms or recurrent hospitalizations despite maximal treatment. NYHA Class: Class IV.
What defines NYHA Functional Class I?
No limitations of physical activity. Ordinary physical activity does not cause HF symptoms (e.g., fatigue, palpitations, dyspnea).
What defines NYHA Functional Class II?
Slight limitation of physical activity. Comfortable at rest, but ordinary physical activity (e.g., walking up stairs) results in HF symptoms.
What defines NYHA Functional Class III?
Marked limitation of physical activity. Comfortable at rest, but minimal exertion (e.g., bathing, dressing) causes HF symptoms.
What defines NYHA Functional Class IV?
Unable to perform physical activity without HF symptoms, or HF symptoms occur at rest (e.g., SOB while sitting in a chair).
What is cardiac output (CO), and what is its formula?
Definition: The volume of blood pumped by the heart in one minute. Formula: CO = HR x SV (Heart Rate x Stroke Volume).
What is stroke volume (SV), and what three factors does it depend on?
Definition: The volume of blood ejected from the left ventricle during one complete heartbeat. Three Factors: Preload (blood volume returning to the heart), afterload (degree of peripheral vasoconstriction or systemic vascular resistance), and cardiac contractility.
How does the body initially compensate for low cardiac output in HFrEF, and what are the longterm consequences?
Initial Compensation: Activates neurohormonal pathways to increase blood volume or the force/speed of contractions, temporarily increasing CO. Long-Term Consequence: Chronically leads to myocyte damage and cardiac remodeling (changes in heart size, composition, and shape, such as hypertrophy or dilatation).
Which neurohormonal pathways are activated in HF, and what happens to the counteracting neurohormones?
Activated Pathways: The renin-angiotensin-aldosterone system (RAAS), the sympathetic nervous system (SNS), and vasopressin. Counteracting Neurohormones: Those that normally counteract these systems (e.g., natriuretic peptides) become insufficient.
Summarize the cascade and physiological effects of RAAS and vasopressin activation in HF.
Renin: Converts angiotensinogen to angiotensin I. Angiotensin-converting enzyme (ACE): Converts angiotensin I to angiotensin II. Angiotensin II: Causes systemic vasoconstriction and stimulates the release of aldosterone (from the adrenal gland) and vasopressin (from the pituitary gland). Aldosterone: Causes sodium and water retention and increases potassium excretion. Vasopressin: Causes vasoconstriction and water retention.
What are the effects of sympathetic nervous system (SNS) activation in HF?
Release of norepinephrine (NE) and epinephrine (Epi) causes an increase in heart rate (HR), contractility (positive inotropy), and vasoconstriction.
By what three general mechanisms do drugs cause or worsen heart failure?
Fluid retention, increased blood pressure, or negative inotropic effects.
Which drugs can cause or worsen heart failure? (Mnemonic: "Drug Information NATION")
Dipeptidyl peptidase 4 (DPP-4) inhibitors: Alogliptin, saxagliptin; Immunosuppressants: TNF inhibitors (e.g., adalimumab, etanercept); Non-dihydropyridine CCBs: Diltiazem and verapamil; Antiarrhythmics: Class I drugs (e.g., flecainide) and dronedarone (Amiodarone and dofetilide are preferred in HF); Thiazolidinediones; Itraconazole; Oncology drugs: Anthracyclines (e.g., doxorubicin), trastuzumab; NSAIDs.
What are the key lifestyle management instructions for a patient's HF action plan?
Monitor and document body weight daily; Notify the provider if symptoms worsen or weight increases by 2– 4 pounds in 1 day or >= 5 pounds in 1 week; Avoid excessive sodium intake (consider restricting to < 1,500 mg/day in those with hypertension); Stop smoking, limit alcohol intake, and avoid illicit drugs; Exercise (if able), reduce weight (if appropriate), and obtain recommended adult vaccines.
What is the role of natural products (omega-3 fatty acids, hawthorn, CoQ10) in heart failure?
Omega-3 fatty acid (fish oil): Reasonable to decrease mortality and CV hospitalizations. Hawthorn and coenzyme Q10: May improve HF symptoms.
How should first-line guideline-directed medical therapy (GDMT) for HFrEF be initiated and dosed?
Medications may be started simultaneously (at low doses) or sequentially (without achieving target doses before initiating the next medication). As tolerated, treatments should be titrated to target doses that demonstrated benefit in clinical studies.
Which compensatory mechanisms, physiological effects, and mortality benefits are associated with Beta-blockers in HF?
Compensatory Mechanism Blocked: Increased SNS (increases HR, increases contractility / + inotropic effect). Mortality Benefit: Yes.
Which compensatory mechanisms, physiological effects, and mortality benefits are associated with ACE inhibitors, ARBs, and ARAs in HF?
Compensatory Mechanism Blocked: Increased RAAS (vasoconstriction / increases afterload, and fluid retention / increases preload). Mortality Benefit: Yes.
Which compensatory mechanisms, physiological effects, and mortality benefits are associated with Sacubitril in HF?
Compensatory Mechanism Targeted: Enhances increased natriuretic peptides (promoting vasodilation and diuresis). Mortality Benefit: Yes.
What are the four first-line mortality-reducing drug classes (GDMT) recommended for all HFrEF patients, along with their key caveats?
ARNI, ACE inhibitor, or ARB: ARNI is preferred over an ACE inhibitor or ARB; Beta-blocker (BB): Select agents only (not a class effect); SGLT2 inhibitor: Must meet eGFR criteria for use; Aldosterone receptor antagonist (ARA): Must meet eGFR and potassium criteria for use.
What is the clinical role and mortality impact of loop diuretics in HFrEF?
Clinical Role: Decreases symptoms by reducing blood volume (counteracting fluid retention / increases preload), which decreases edema and congestion. Mortality Benefit: No (reduces symptoms only).
When is hydralazine/isosorbide dinitrate indicated in HFrEF, and what is its clinical benefit?
Indication: Self-identified Black patients who remain symptomatic on optimized (titrated to target doses) first-line medications, or patients who cannot tolerate a RAAS inhibitor. Benefit: Decreases morbidity and mortality.
What is the clinical benefit and requirement for using ivabradine in HFrEF?
Benefit: Decreases risk of hospitalization and CV death. Requirement: Must meet heart rate and rhythm criteria for use.
What is the mechanism and clinical benefit of digoxin in HFrEF?
Mechanism: Increases cardiac output (CO). Benefit: Decreases symptoms and cardiac hospitalizations (does not reduce mortality).
When is vericiguat used in HFrEF, and what is its clinical benefit?
Indication: After a recent HF hospitalization or need for IV diuretics. Benefit: Decreases risk of hospitalization and CV death.
How should patients with Heart Failure with Improved EF (HFimpEF) be managed?
Patients with HFimpEF (baseline LVEF
What is the primary recommended drug class for HFmrEF (LVEF 41–49%) and HFpEF (LVEF >= 50%), and what other treatments may be considered?
Primary Recommendation: SGLT2 inhibitors (demonstrated benefit in decreasing HF hospitalizations and cardiovascular mortality). Other Treatments Considered: ARNI/ACE inhibitor/ARB, BB, ARA, and PRN diuretics— especially if LVEF is on the lower end of the spectrum or needed to control comorbid conditions that can exacerbate HF (e.g., hypertension, heart rate control in atrial fibrillation).
What are the general clinical effects of RAAS inhibitors (ARNI, ACE inhibitor, or ARB) in heart failure?
Recommended first-line in all HF patients regardless of symptom severity; Decrease RAAS activation, resulting in decreased preload and afterload; Decrease cardiac remodeling, improve left ventricular function, and decrease morbidity and mortality; Benefits are a class effect (any drug in the class can be used).
Why should you avoid combining more than one RAAS inhibitor (e.g., ACE inhibitor + ARB, especially with an ARA)?
Due to an increased risk of hyperkalemia and renal insufficiency.
How does the risk of angioedema compare across ACE inhibitors, sacubitril, and ARBs, and what is the rule for testing purposes?
ACE inhibitors & Sacubitril: Can cause angioedema because they increase bradykinin levels. ARBs: Lower risk of angioedema because they do not increase bradykinin levels (clinicians may use clinical judgment to prescribe in patients with a history of angioedema). For Testing Purposes: An ACE inhibitor, ARB, or ARNI should be avoided in patients with a history of angioedema.
What is the mechanism of action of sacubitril (neprilysin inhibitor) in an ARNI?
Neprilysin is an enzyme that degrades beneficial vasodilatory peptides (e.g., natriuretic peptides, adrenomedullin, substance P, bradykinin). Inhibiting neprilysin increases these peptides, counteracting RAAS by causing vasodilation and diuresis.
What is the starting dose, target dose, and washout requirement for Sacubitril/Valsartan (Entresto)?
Starting Dose: 24/26 mg BID (or 49/51 mg BID if previously taking a moderate-high dose ACE inhibitor or ARB). Target Dose: 97/103 mg BID. ACE Inhibitor Switch: Requires a 36- hour washout period when switching between an ACE inhibitor and ARNI. ARB Switch: No washout required; take the first sacubitril/valsartan dose when the next ARB dose is due.
What is the boxed warning and what are the contraindications for Sacubitril/Valsartan (Entresto)?
Boxed Warning: Can cause injury and death to the developing fetus when used in the 2nd and 3rd trimesters; discontinue as soon as pregnancy is detected. Contraindications: History of angioedema; use with or within 36 hours of an ACE inhibitor; use with aliskiren in diabetes.
What are the warnings, side effects, and monitoring parameters for Sacubitril/Valsartan (Entresto)?
Warnings: Angioedema, hyperkalemia, renal impairment (increased risk with bilateral renal artery stenosis), and hypotension/dizziness (increased risk if volume-depleted, e.g., concurrent diuretic use). Side Effects: Same as warnings, plus cough (due to increased bradykinin). Monitoring: Blood pressure (BP), potassium (K), renal function (SCr), signs/ symptoms of HF, and angioedema.
How do the mechanisms of action of ACE inhibitors and ARBs compare?
ACE inhibitors: Block the conversion of angiotensin I to angiotensin II, and also block the degradation of bradykinin (which contributes to cough and angioedema). ARBs: Block angiotensin II from binding to the angiotensin II type-1 (AT1) receptor. Shared Result: Both decrease vasoconstriction and aldosterone secretion.
What are the starting and target HF doses for Captopril, Enalapril, Fosinopril, and Lisinopril?
Captopril: Start 6.25 mg TID (1 hr before meals); Target 50 mg TID. Enalapril (Vasotec, Epaned oral solution): Start 2.5 mg PO BID; Target 10–20 mg PO BID. Fosinopril: Start 5–10 mg daily; Target 40 mg daily. Lisinopril (Zestril, Qbrelis oral solution): Start 2.5–5 mg daily; Target 20–40 mg daily.
What are the starting and target HF doses for Perindopril, Quinapril, Ramipril, and Trandolapril?
Perindopril: Start 2 mg daily; Target 8–16 mg daily. Quinapril (Accupril): Start 5 mg BID; Target 20 mg BID. Ramipril (Altace): Start 1.25–2.5 mg daily; Target 10 mg daily. Trandolapril: Start 1 mg daily; Target 4 mg daily.
What is the boxed warning and what are the contraindications for ACE inhibitors?
Boxed Warning: Can cause injury and death to the developing fetus when used in the 2nd and 3rd trimesters; discontinue as soon as pregnancy is detected. Contraindications: History of angioedema; use with or within 36 hours of sacubitril/valsartan; use with aliskiren in diabetes.
What are the warnings, side effects, and monitoring parameters for ACE inhibitors?
Warnings: Angioedema, hyperkalemia, renal impairment (increased risk with bilateral renal artery stenosis), and hypotension/dizziness (increased risk if volume-depleted, e.g., concurrent diuretic use). Side Effects: Same as warnings, plus cough and headache. Monitoring: Blood pressure (BP), potassium (K), renal function (SCr), signs/symptoms of HF, and angioedema.
What are the starting and target HF doses for Candesartan, Losartan, and Valsartan?
Candesartan (Atacand): Start 4–8 mg daily; Target 32 mg daily. Losartan (Cozaar): Start 25–50 mg daily; Target 50–150 mg daily. Valsartan (Diovan): Start 40 mg BID; Target 160 mg BID.
How does the safety/side effect profile of ARBs differ from ACE inhibitors?
Same as ACE inhibitors except: no cough, less angioedema, and no washout period required with sacubitril/ valsartan.
What are the major drug interactions associated with ARNIs, ACE inhibitors, and ARBs?
Hyperkalemia: Use caution with other potassium-increasing drugs (e.g., potassium-sparing diuretics) and avoid potassium-containing salt substitutes. Washout Period: 36-hour washout required when switching between an ACE inhibitor and ARNI (no washout needed between an ARB and ARNI). Dual RAAS Blockade: Do not combine more than one RAAS inhibitor (e.g., ACE inhibitor + ARB or ARNI) due to increased risk of renal impairment, hypotension, and hyperkalemia. NSAIDs: Can increase the risk of renal impairment (especially in elderly, volumedepleted, or impaired baseline renal function). Lithium: Can decrease lithium renal clearance and increase risk of lithium toxicity.
What is the mechanism of action of beta-blockers in heart failure, and which specific agents are recommended?
Mechanism: Antagonize the effects of catecholamines (especially NE) at beta-1, beta-2, and/or alpha-1 adrenergic receptors to improve cardiac function and decrease morbidity and mortality. Recommended Agents: Not a class effect; only bisoprolol, carvedilol (IR and CR), or metoprolol succinate ER should be used.
What are the starting dose, target dose, and formulation rules for Metoprolol succinate ER (Toprol XL, Kapspargo Sprinkle) in HF?
Starting Dose: 12.5–25 mg daily. Target Dose: 200 mg daily. Formulation Note: Metoprolol tartrate (Lopressor) is not recommended.
What are the key administration and conversion notes for Metoprolol?
IV to PO Conversion: Metoprolol IV is not equivalent to PO (IV:PO ratio is 1:2.5). Tablet Administration: Metoprolol succinate tablets can be cut in half (do not crush or chew); take with or immediately after meals. Capsule Administration: Extended-release capsules can be opened and contents sprinkled on a teaspoonful of soft food (e.g., applesauce, yogurt, or pudding).
What are the starting and target HF doses for Bisoprolol?
Starting Dose: 1.25 mg daily. Target Dose: 10 mg daily.
What is the boxed warning and what are the contraindications for beta-blockers?
Boxed Warning: Do not discontinue abruptly (especially in CHD/IHD); gradually taper over 1–2 weeks to avoid acute tachycardia, hypertension, and ischemia. Contraindications: Severe bradycardia, 2nd/3rd degree AV block or sick sinus syndrome (unless permanent pacemaker is in place), and cardiac failure or shock.
What are the warnings, side effects, and monitoring parameters for beta-1 selective blockers?
Warnings: Use caution in diabetes (can worsen hypoglycemia and mask hypoglycemic symptoms), bronchospastic diseases (e.g., asthma, COPD), and Raynaud's/other peripheral vascular diseases; can mask signs of hyperthyroidism (e.g., tachycardia). Side Effects: Bradycardia, hypotension, CNS effects (e.g., fatigue, dizziness, depression), impotence, and cold extremities (can exacerbate Raynaud's). Monitoring: Heart rate (HR), blood pressure (BP), and signs/symptoms of HF.
What is the receptor selectivity, starting dose, and target dose for Carvedilol IR (Coreg) and Carvedilol CR (Coreg CR)?
Receptor Selectivity: Non-selective beta-blocker and alpha-1 blocker. Immediate Release (IR): Start 3.125 mg BID; Target dose is 25 mg BID (
What additional contraindications, warnings, and side effects apply to Carvedilol compared to beta-1 selective blockers?
Contraindications: Severe hepatic impairment and bronchial asthma. Warning: Intraoperative floppy iris syndrome (has occurred in cataract surgery patients taking or previously treated with an alpha-1 blocker). Side Effects: Edema and weight gain.
What are the key administration and conversion notes for Carvedilol?
Food Requirement: Take with food to decrease absorption rate and orthostatic hypotension risk. CR Capsule Administration: Swallow whole; if needed, the capsule can be opened and contents sprinkled on a spoonful of applesauce. IR to CR Conversion: Carvedilol CR bioavailability is lower than IR; dose conversions are not 1:1 (e.g., IR 3.125 mg BID = CR 10 mg daily).
What are the major drug interactions associated with beta-blockers?
Hypoglycemics: Can enhance the hypoglycemic effects of insulin and sulfonylureas and mask some symptoms of hypoglycemia (e.g., shakiness, palpitations, anxiety). HR-Lowering Drugs: Use caution with other drugs that decrease HR (e.g., digoxin, verapamil, diltiazem, amiodarone). CYP2D6: Carvedilol and metoprolol are CYP450 2D6 substrates that can interact with CYP2D6 inhibitors or inducers. P-gp Inhibition: Carvedilol inhibits P-gp and can increase concentrations of P-gp substrates (e.g., digoxin, cyclosporine, dabigatran, ranolazine).
What is the proposed mechanism of SGLT2 inhibitors in heart failure, and what is the renal cutoff for initiation?
Mechanism: Likely related to reduced sodium reabsorption, diuresis, and a decrease in preload and/or afterload (which decreases mortality and hospitalizations). Renal Cutoff: Generally should not be initiated for HF if eGFR < 20–25 mL/min/1.73 m2 (cutoffs are medication-specific).
Which SGLT2 (and SGLT1/2) inhibitors are used in heart failure, and what are their doses?
Dapagliflozin (Farxiga): 10 mg PO daily (fixed dose, no titration; first-line). Empagliflozin (Jardiance): 10 mg PO daily (fixed dose, no titration; first-line). Sotagliflozin (Inpefa): Dual SGLT1/2 inhibitor indicated to decrease CV death, hospitalization, and urgent visits in patients with HF.
How do aldosterone receptor antagonists (ARAs) work in HF, and how do spironolactone and eplerenone differ in selectivity?
Mechanism & Benefit: Compete with aldosterone at receptor sites in the distal convoluted tubule and collecting ducts of the nephron; decrease sodium/ water retention, cardiac remodeling, sudden cardiac death, morbidity, and mortality. Spironolactone: Non-selective; also blocks androgen and exhibits endocrine side effects. Eplerenone: Selective; does not exhibit endocrine side effects.
What are the starting doses, target doses, and formulation warnings for Spironolactone (Aldactone, CaroSpir)?
Aldactone (Tablet): Start 12.5–25 mg daily; Target dose 25–50 mg daily. CaroSpir (Oral suspension): Start 10–20 mg daily; may increase to 37.5 mg daily. Formulation Note: Oral suspension is not therapeutically equivalent to tablets (doses > 100 mg can cause supratherapeutic levels; only use tablets for doses > 100 mg).
What are the starting and target HF doses for Eplerenone (Inspra)?
Starting Dose: 25 mg daily. Target Dose: 50 mg daily.
What are the contraindications and initiation warnings (lab thresholds) for Aldosterone Receptor Antagonists (ARAs)?
Contraindications: Hyperkalemia, severe renal impairment, Addison disease (spironolactone), and taking strong CYP3A4 inhibitors (eplerenone). Initiation Warnings: Do not initiate for HF if K >= 5 mEq/L, CrCl (eGFR)
What are the side effects and monitoring parameters for Aldosterone Receptor Antagonists (ARAs)?
General Side Effects: Hyperkalemia (increased risk if renal impairment), dizziness, and hyperchloremic metabolic acidosis (rare). Spironolactone-Specific: Gynecomastia, breast tenderness, impotence, irregular menses, and amenorrhea. Eplerenone-Specific: Increased triglycerides (TGs). Monitoring: Blood pressure (BP), potassium (K), renal function, fluid status, and signs/symptoms of HF.
What are the major drug interactions associated with Aldosterone Receptor Antagonists (ARAs)?
Hyperkalemia: Use caution with other drugs that increase potassium (e.g., RAAS inhibitors). Triple Combination: Do not use triple combination (e.g., ACE inhibitor + ARB or ARNI
What is the mechanism of action and clinical role of loop diuretics in heart failure?
Mechanism: Inhibit the Na-K-2Cl cotransporter in the thick ascending limb of the loop of Henle, increasing excretion of sodium, potassium, chloride, magnesium, calcium, and water. This decreases fluid volume (decreases preload), reduces congestive symptoms, making it easier for the heart to pump, and restores euvolemia ("dry" weight). Clinical Role: Do not improve survival, but are often required for symptom control. Use the lowest effective dose to prevent overdiuresis (dehydration, hypotension, renal impairment). Poor Response: Adding a thiazide diuretic, such as metolazone, can be useful.
What are the oral starting/usual doses, maximum daily doses, and available formulations for the four loop diuretics?
Furosemide (Lasix, Furoscix, Onyu): Oral 20–40 mg daily or BID; Max 600 mg/day (Tablet, injection, oral solution, SC on-body infusor). Bumetanide (Bumex, Enbumyst): Oral 0.5–1 mg daily or BID; Max 10 mg/day (Tablet, injection, nasal spray). Torsemide (Soaanz): Oral 10–20 mg daily; Max 200 mg/day (Tablet). Ethacrynic Acid (Edecrin): Oral 50–200 mg daily; Max 400 mg/day (Tablet, injection).
What is the boxed warning, contraindications, and warnings for loop diuretics?
Boxed Warning: Can cause profound diuresis resulting in fluid and electrolyte depletion. Contraindications: Anuria; hepatic coma (bumetanide and torsemide only). Warnings: Sulfa allergy (not likely to cross-react; does not apply to ethacrynic acid); Ototoxicity (hearing loss, tinnitus, and vertigo; increased risk with ethacrynic acid or rapid IV administration); Acute kidney injury (due to excessive fluid loss).
What are the electrolyte/lab changes, side effects, and monitoring parameters for loop diuretics?
Decreased Electrolytes: Na, K, Cl, Mg, Ca (different from thiazides, which increase Ca). Increased Electrolytes/Labs: HCO3 (metabolic alkalosis), uric acid (UA), blood glucose (BG), triglycerides (TGs), and total cholesterol. Other Side Effects: Orthostatic hypotension, photosensitivity, and myalgias. Monitoring: Renal function, fluid status (input/output, weight), BP, electrolytes, and signs/symptoms of HF.
What are the key administration, storage, and formulation notes for loop diuretics?
Timing: Take early in the day to avoid nocturia. Furosemide Injection Storage: Store at room temperature (refrigeration causes crystals to form, which may dissolve upon warming); solution must be clear—do not use if yellow in color. Subcutaneous Furosemide: Furoscix and Onyu are administered using an on-body infusor that delivers furosemide as a SC infusion. Light Sensitivity: Bumetanide and furosemide injections are light-sensitive (store in amber bottles); IV admixtures do not require light protection.
What are the oral equivalent doses and IV-to-PO conversion ratios for loop diuretics?
Oral Equivalent Dosing: Furosemide 40 mg = Torsemide 20 mg = Bumetanide 1 mg = Ethacrynic acid 50 mg. Furosemide IV:PO Ratio: 1:2 (furosemide 20 mg IV = furosemide 40 mg PO). Bumetanide & Ethacrynic Acid IV:PO Ratio: 1:1.
What are the four major drug interactions associated with loop diuretics?
NSAIDs: Avoid; the increased sodium and water retention can decrease the effect of loop diuretics and may also cause renal impairment. Ototoxic Drugs: Additive risk for ototoxicity when used with other ototoxic drugs. Thiazide Diuretics: Watch for additive diuresis and electrolyte abnormalities when used in combination. Lithium: Can alter lithium levels, leading to lithium toxicity or inadequate treatment.
Practice Conversion: A patient on furosemide 40 mg IV BID is being switched to oral bumetanide. What is the equivalent daily oral dose of bumetanide?
Step 1 (IV Furosemide to PO Furosemide): Total daily IV furosemide is 80 mg IV. Using a 1:2 IV:PO ratio, 80 mg IV / X mg PO = 1 mg IV / 2 mg PO -> X = 160 mg PO furosemide. Step 2 (PO Furosemide to PO Bumetanide): Using the 40 mg:1 mg oral equivalence, 160 mg PO furosemide / X mg PO bumetanide = 40 mg PO furosemide / 1 mg PO bumetanide -> X = 4 mg PO bumetanide daily.
What are the mechanisms of action of hydralazine and nitrates, and why are they combined in heart failure?
Hydralazine: Direct arterial vasodilator, which decreases afterload. Nitrates (e.g., isosorbide dinitrate): Increase the availability of nitric oxide, causing venous vasodilation and decreasing preload. Monotherapy Rule: There is no role for monotherapy with either hydralazine or an oral nitrate in the treatment of HF.
What are the two primary clinical indications for hydralazine/isosorbide dinitrate in heart failure?
Alternative to RAAS Inhibitors: Improves survival in HF (to a lesser degree than RAAS inhibitors) and can be used in patients who cannot tolerate an ARNI, ACE inhibitor, or ARB. AddOn Therapy: Indicated in self-identified Black patients who remain symptomatic despite optimal treatment (e.g., ARNI or ACE inhibitor or ARB + beta-blocker + ARA + SGLT2 inhibitor).
What are the starting and target doses for Hydralazine/Isosorbide Dinitrate (BiDil) and Hydralazine, and does BiDil cause nitrate tolerance?
Hydralazine/Isosorbide Dinitrate (BiDil): Start 20/37.5 mg TID (1 tab TID); Target dose 40/75 mg TID (2 tabs TID). Hydralazine: Start 25– 50 mg TID–QID; Target dose 300 mg/day in divided doses. Tolerance Note: No nitrate tolerance occurs with BiDil.
What are the contraindications, warnings, side effects, and monitoring parameters for Hydralazine?
Contraindications: Mitral valve rheumatic heart disease and coronary artery disease (CAD). Warning: Drug-induced lupus erythematosus (DILE — dose and duration related). Side Effects: Peripheral edema, headache, flushing, palpitations, reflex tachycardia, nausea/ vomiting, peripheral neuritis, blood dyscrasias, and hypotension. Monitoring: Heart rate (HR), blood pressure (BP), ANA titer, and signs/symptoms of HF.
What is the preferred nitrate formulation for systolic HF, and what are its starting and target doses?
Preferred Formulation: Isosorbide dinitrate IR/ER (Isordil Titradose). Starting Dose: 20–30 mg TID–QID. Target Dose: 120 mg daily in divided doses.
What are the contraindications, side effects, monitoring parameters, and drug interactions for Isosorbide dinitrate?
Contraindications / Drug Interactions: Do not use with PDE-5 inhibitors (e.g., avanafil, sildenafil, tadalafil, vardenafil) or riociguat, as the combination can cause severe hypotension. Side Effects: Hypotension, headache, dizziness, tachyphylaxis (requires a 10–12 hour nitrate-free interval), and syncope. Monitoring: Heart rate (HR), blood pressure (BP), and signs/symptoms of HF.
What is the mechanism of action, clinical benefit, and patient selection criteria for Ivabradine in heart failure?
Mechanism: Disrupts the "funny" current (If) in the sinoatrial (SA) node, decreasing the rate of firing and lowering HR. Clinical Benefit: Decreases hospitalizations for worsening HF and may also reduce CV death. Criteria for Use: Recommended as adjunct treatment in symptomatic patients already receiving GDMT (including target or maximallytolerated doses of beta-blockers, unless contraindicated) who have a normal sinus rhythm and a resting HR >= 70 BPM.
What is the dosing and target resting heart rate for Ivabradine (Corlanor)?
Starting Dose: 5 mg PO BID; after two weeks, adjust dose based on HR. Maintenance Dose: 2.5–7.5 mg PO BID. Target Resting HR: Between 50–60 BPM.
What are the contraindications for Ivabradine (Corlanor)?
Acute decompensated heart failure (ADHF); Sick sinus syndrome, sinoatrial block, or 3rd degree AV block (unless a permanent pacemaker is in place); Clinically significant hypotension or bradycardia; HR maintained exclusively by a pacemaker; Severe hepatic impairment; Concurrent use with strong CYP3A4 inhibitors.
What are the warnings, side effects, and monitoring parameters for Ivabradine (Corlanor)?
Warnings: Can cause bradycardia (which can increase risk of QT prolongation and ventricular arrhythmias; not recommended in 2nd degree AV block), increased risk of atrial fibrillation, and fetal toxicity (females should use effective contraception). Side Effects: Bradycardia, hypertension, and luminous phenomena (phosphenes — seeing flashes of light). Monitoring: Heart rate (HR), ECG, and blood pressure (BP).
What are the major drug interactions associated with Ivabradine?
CYP3A4: Do not use with moderate or strong CYP3A4 inhibitors, or strong CYP3A4 inducers. HR-Lowering Drugs: Use caution with other drugs that decrease HR (e.g., digoxin, beta-blockers, clonidine, non-DHP CCBs, amiodarone, and dexmedetomidine).
What is the mechanism of action and clinical role of Digoxin in heart failure?
Mechanism: Inhibits the Na-K-ATPase pump in myocardial cells, causing a positive inotropic effect (increases CO). It also exerts a parasympathetic effect, slowing AV nodal conduction and causing a negative chronotropic effect (decreases HR). Clinical Role: Does not improve survival, but can decrease HF-related hospitalizations. Can be added to GDMT to improve symptoms, exercise tolerance, and quality of life, or used for HR control in patients with atrial fibrillation (AF), HFrEF, and low blood pressure.
What factors determine the starting dose of Digoxin, what is its therapeutic range in HF, and what electrolyte levels should be maintained?
Starting Dose Factors: Based on renal function, body mass, and age (a lower dose is used in patients with renal insufficiency, lower body weight, or older age). Therapeutic Range (HF): 0.5–0.9 ng/mL (higher range used for atrial fibrillation). Electrolyte Goals: Since hypokalemia and hypomagnesemia increase the risk for digoxin toxicity, maintain potassium between 4–5 mEq/L and magnesium > 2 mEq/L.